AptarGroup, a global leader in drug delivery and consumer product dispensing, has announced that its Unidose (UDS) Powder Nasal Spray System is now part of ENA Respiratory’s Phase II clinical trial of INNA‑051, an investigational nasal spray aimed at reducing symptomatic viral respiratory infections. 

 

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention.

 

ENA Respiratory, a clinical-stage pharmaceutical company focused on antiviral host defense enhancers, recently dosed the first participants in its study. 

 

The trial is evaluating the safety, tolerability, and potential effectiveness of the once-weekly nasal spray in adults at higher risk of viral respiratory exposure. Conducted in a community-based setting, the study aims to assess INNA‑051’s potential to reduce the burden of symptomatic respiratory viral illness.

 

Aptar Pharma’s UDS powder nasal delivery system is designed to deliver a single, precise dose of dry powder with consistent performance, supporting reliable administration in clinical trials. The ready-to-use device is simple to operate and ideal for nasal powder formulations requiring enhanced stability.

 

The system will be housed in Aptar CSP Technologies’ container closure system, featuring 3-Phase Activ-Polymer technology that protects the powder from moisture. Internal safety features prevent accidental activation during insertion, removal, or if dropped, ensuring dependable patient access.

 

“Aptar Pharma is proud to support ENA Respiratory in the clinical development of INNA‑051 through the use of our UDS powder nasal delivery system,” said Alex Theodorakis, President, Aptar Pharma Prescription. 

 

“By combining reliable intranasal delivery technologies with comprehensive technical and regulatory expertise, we help our partners advance innovative therapies intended to address unmet needs in respiratory health.”